Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Most people who start Wegovy or Ozempic lose weight fast at first. The appetite shrinks, the scale moves, and the drug seems to be working perfectly. Then one day, everything just stops.
No more progress. Same drug, same dose, same routine, but the weight loss simply stalls. Doctors see it all the time, and patients find it deeply discouraging.
A team of researchers at the National Institutes of Health (NIH) wanted to understand exactly why this happens. They dug into the brain chemistry behind it, and what they found was genuinely interesting. They published their results in the journal Nature Metabolism.
The team, led by Andrew Routhous, zoomed in on brain neurons that semaglutide targets directly. Semaglutide is the active compound in both Wegovy and Ozempic. Using a special fluorescence imaging tool, they watched live molecular activity inside mouse brain tissue in real time.
They zeroed in on a small region called the area postrema. This part of the brain helps regulate appetite. Inside it, they spotted something telling: a molecule called cAMP, short for cyclic adenosine monophosphate, controls how strongly semaglutide works.
Here is where it gets interesting. When semaglutide activates neurons, it pushes cAMP levels up. That spike is what tells the brain to suppress hunger. Higher cAMP means stronger appetite control. So far, so good.
But not every neuron plays along. Some neurons held their cAMP levels high after the drug kicked in. Others spiked briefly, then crashed back down. That difference, the team found, explains why some patients respond better than others, and why the drug eventually loses steam over time.
So what causes the cAMP to drop? The culprit turned out to be an enzyme called PDE4. This enzyme breaks cAMP down naturally. In neurons with high PDE4 activity, the drug’s signal gets cut short before it can do its full job.
To test a fix, the researchers brought in a drug called roflumilast, a known PDE4 inhibitor. They gave it alongside semaglutide in mice. The result was clear: cAMP levels stayed elevated longer, and the hunger-suppressing effect held on.
That said, this is still early-stage science. The study ran on mice, and the team only watched neurons for a few hours at a stretch. They plan to run longer studies tracking changes over days and weeks before drawing bigger conclusions.
Still, the direction looks promising. GLP-1 drugs like Wegovy, Ozempic, and Mounjaro have already transformed how doctors treat obesity and type 2 diabetes. They work well, but the plateau problem has always been a weak spot.
If follow-up research confirms these findings in humans, combining GLP-1 drugs with PDE4 inhibitors could help patients break through that wall. On top of that, stabilizing cAMP signaling might even allow patients to take their medication less often while keeping the same effect. For anyone managing obesity long term, that would be a real and welcome shift.
